Cerevasc today announced the first-in-human use of its eShunt system to treat medically refractory idiopathic intracranial hypertension (IIH).

Please provide your email address to receive an email when new articles are posted on . Later idiopathic intracranial hypertension diagnoses occurred less often in women with slightly lower ...

Among women with idiopathic intracranial hypertension (IIH) and a body mass index (BMI) of 35 or higher, bariatric surgery was a more effective means of reducing intracranial pressure and sustaining ...

Our findings suggest that GLP-1 therapy holds real promise. While a randomized trial is still needed, the fact that many patients with IIH already qualify for GLP-1s due to diabetes or obesity means ...

Int Ophthalmol Clin. 2014;54(1):27-41. Much of the data supporting weight loss as treatment for IIH comes from retrospective studies or class III evidence. There has been a long-standing need for ...

Patients with ‘blinding’ headaches known as Idiopathic Intercranial Hypertension (IIH) could be treated with an injectable peptide used for type 2 diabetes, a new trial has found. The study, published ...

Please provide your email address to receive an email when new articles are posted on . AUSTIN, Texas — Venous manometry and neuroimaging may provide additional value when diagnosing patients who do ...

The study goal was to identify risk factors for progressive visual field loss among participants with idiopathic intracranial hypertension and mild visual loss in the Idiopathic Intracranial ...